EQUASENS: H1 2022 Results – GlobeNewswire

Villers Les Nancy, FRANCE
Villers-lès-Nancy, 22 September 2022 – 6:00 p.m. (CET)
H1 2022 Results
* Impact IP BOX option + financial returns
** Impact of higher overhead costs vs. H1 2021
The financial statements for the six-month period ended 30 June 2022 were reviewed and adopted by EQUASENS’ Board of Directors, chaired by Thierry CHAPUSOT, on 22 September 2022. These interim consolidated financial statements were subject to a limited review by the Statutory Auditors.
Equasens Group recorded 10.30% growth in revenue for the six months ended June 30, 2022, to €103.57m compared to H1 2021. Like-for-like, revenue rose 7.68% to €101.11m, confirming the positive impact of PROKOV EDITIONS’ acquisition in Q4 2021.
The Group’s Current Operating Income rose 5.37% to €25.76m at June 30, 2022, largely in response to the increase in non-recurring overhead costs from one year earlier. For the 2022 full-year, the current operating margin is expected to follow the same trends as in previous years.
Net Profit on that basis amounted to €20.95m (+18.92%) and Net Profit Attributable to Owners of the Company to €19.73m (+18.96%). At 30 June 2022, Basic Earnings per Share amounted to €1.31, up from € 1.10 one year earlier (+19.10%).
        At 30 June 2022, Equasens Group’s gross cash position increased to €121.74m, of from €107.87m at 31 December 2021.
With a net cash position (net of all loans) of €45.45m, Equasens Group maintains a high degree of autonomy and a significant investment capacity to take advantage of future acquisition opportunities.
Equity attributable to owners of the Company at 30 June 2022 amounted to €161.78m.
Dominique PAUTRAT, having stepped down as Chief Executive Officer of Equasens Group to become Chairman of the Board of Directors of La Coopérative WELCOOP, parent company of Equasens Group, as of April 22, 2022, Denis SUPPLISSON was appointed Chief Executive Officer in his place as from 23 April 2022. Grégoire de ROTALIER, appointed in July 2020, remains Deputy CEO, while continuing to develop the AXIGATE LINK Division he manages, and contributes to Equasens Group’s cross-corporate projects.
The Extraordinary General Meeting of the Shareholders held on 6 May at the company’s headquarters adopted the resolution to change the company’s name to EQUASENS.
This new name highlights the interoperability of solutions developed for patients and healthcare professionals and healthcare establishments while reinforcing the Group’s “Patient-Centred” positioning initiated over 10 years ago:
This new name thus provides a perfect fit with the Group’s tagline Technology for a more human experience.
“This change in name from Pharmagest to Equasens better reflects the Group’s new identity in terms of the diversity of its activities and new markets. Today, our Group is no longer solely a software developer for pharmacies but is also a leading provider of healthcare solutions in Europe. For more than 10 years now, we have expanded our positioning focused on the pharmacy market to a provider of IT solutions to all healthcare professionals in France and tomorrow in Europe” declared Thierry CHAPUSOT, Chairman of the Board of Directors of the Equasens Group.
Therapeutic compliance is a key issue at the European level in the management of elderly and chronically ill patients. In 2022, continuing to implement a strategy focused on patients and effective medication compliance, the Group has increased its shareholdings in three of its European subsidiaries:
These different operations will help Equasens Group accelerate its expansion and reinforce its presence in several European countries. In particular:
Equasens Group’s value-added differentiation has been reinforced by the recent qualification of its software offerings for inclusion in the Ségur programme, solidifying its position on the cutting edge of its market as key contributor to and leader in the healthcare ecosystem.
With a net cash position (net of all loans) of €45.45m, Equasens Group maintains a high degree of autonomy and a significant investment capacity to take advantage of future acquisition opportunities.
Equasens Group remains confident and confirms its targets for growth and profitability in 2022, in view of the non-recurring nature of the expenses of the first half.
Financial calendar:
About Equasens Group:
With more than 1,200 employees fulfilling a vital role as “Citizens in the Service of Health and Well-Being”, Equasens Group is today a key player in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centres) in both primary and secondary care sectors.
With operations in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group is currently developing the leading healthcare platform and a unique ecosystem in France and Europe benefiting people by making available the very best of technology.
Listed on Euronext Paris™ – Compartment A
Included in the Euronext Tech Leaders segment and the European Rising Tech label
Indexes: MSCI GLOBAL SMALL CAP – GAÏA Index 2020CAC® SMALL and CAC® All-Tradable
Eligible for the Deferred Settlement Service (“Service à Réglement Différé” – SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR0012882389 – Ticker Code: EQS
For all the latest news on Equasens Group go to www.equasens.com
Analyst and Investor Relations:
Chief Administrative and Financial Officer: Jean-Yves SAMSON
Tel. +33 (0) 83 15 90 67 – [email protected]
Media Relations:
Tel. +33 (0)1 39 97 61 22 – [email protected]
1 “Ségur referencement”: a mechanism enabling qualifying software developers to apply for funding under the French “Ségur” digital health investment programme.



Leave a Comment